Pollastri Alessio, Kovacs Peter, Keller Maria
Medical Department III-Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig 04103, Germany.
Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Center Munich at the University of Leipzig and University Hospital Leipzig, Leipzig 04103, Germany.
J Endocr Soc. 2025 Jan 15;9(2):bvaf006. doi: 10.1210/jendso/bvaf006. eCollection 2025 Jan 6.
Metabolic diseases affect a consistent part of the human population, leading to rising mortality rates. This raises the need for diagnostic tools to monitor the progress of these diseases. Lately, circulating cell-free DNA (cfDNA) has emerged as a promising biomarker for various metabolic diseases, including obesity, type 2 diabetes, and metabolic-associated fatty liver disease. CfDNA is released from apoptotic and necrotic cells into the bloodstream and other body fluids, and it retains various molecular signatures of its tissue of origin. Thus, cfDNA load and composition can reflect tissue pathologies and systemic metabolic dysfunctions. In addition to its potential as a diagnostic biomarker, interest in cfDNA derives from its recently discovered role in adipose tissue inflammation in obesity. This review discusses detection methods and clinical significance of cfDNA in metabolic diseases.
代谢性疾病影响着相当一部分人群，导致死亡率不断上升。这就需要诊断工具来监测这些疾病的进展。最近，循环游离DNA（cfDNA）已成为包括肥胖症、2型糖尿病和代谢相关脂肪性肝病在内的各种代谢性疾病的一种有前景的生物标志物。CfDNA从凋亡和坏死细胞释放到血液和其他体液中，并保留其起源组织的各种分子特征。因此，cfDNA的负荷和组成可以反映组织病理学和全身代谢功能障碍。除了作为诊断生物标志物的潜力外，对cfDNA的兴趣还源于其最近在肥胖症脂肪组织炎症中发现的作用。本文综述了cfDNA在代谢性疾病中的检测方法及临床意义。
